Literature DB >> 4150141

Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man.

S Vickers, E K Stuart, J R Bianchine, H B Hucker, M E Jaffe, R E Rhodes, W J Vandenheuvel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4150141

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


× No keyword cloud information.
  10 in total

1.  Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption.

Authors:  J M Rabey; Y Vered; H Shabtai; E Graff; A D Korczyn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

2.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

4.  Phosphaturic effect of dopamine in dogs. Possible role of intrarenally produced dopamine in phosphate regulation.

Authors:  J L Cuche; G R Marchand; R F Greger; R C Lang; F G Knox
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

Review 5.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Potentiation of ethanol narcosis by dopamine- and l-DOPA-based isoquinolines.

Authors:  A Marshall; M Hirst
Journal:  Experientia       Date:  1976-02-15

7.  COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).

Authors:  K M Jorga; D J Nicholl
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

8.  Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Authors:  E Bredberg; H Lennernäs; L Paalzow
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

9.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

10.  Disruption of aminergic signalling reveals novel compounds with distinct inhibitory effects on mosquito reproduction, locomotor function and survival.

Authors:  Silke Fuchs; Ermelinda Rende; Andrea Crisanti; Tony Nolan
Journal:  Sci Rep       Date:  2014-07-02       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.